Page 58 - Predicting survival in patients with spinal bone metastasesL

CHAPTER IV
Table 2. Primary tumor, related survival and clinical profile. UCC: urothelial cell carcinoma. ACUP: adenocarcinoma of unknown primary. CI: confidence interval.
Primary tumor
Number(%)
Median survival (95%CI)
Profile
Breast Thyroid
Prostate Kidney
Ovary Osteosarcoma Uterus sarcoma
Lung
Colon
UCC
ACUP
Esophagus Melanoma Pancreaticobiliary Ewing’s Sarcoma Cervix Endometrium Stomach
Liver Tongue
299 (29) 13 (1)
215 (21) 60 (6) 8 (1)
9 (1)
4 (<1)
250 (24) 55 (5) 27 (3) 22 (2) 20 (2) 17 (2) 11 (1) 10 (1) 7 (1)
5 (1) 4 (<1) 4 (<1) 3 (<1)
18.6 (14.9-22.2) 4.8 (0.0-24.9)
6.6 (5.2-8.1) 4.5 (2.6-6.4) 4.9 (2.3-7.6) 6.3 (0.0-12.6) 4.6 (0.0-10.0)
1.9 (1.5-2.4) 3.2 (1.8-4.5) 1.7 (0.9-2.6) 2.4 (0.9-3.8) 1.7 (0.1-3.3) 1.2 (0.5-1.8) 1.7 (1.2-2.2) 1.9 (0.3-3.5) 2.3 (0.0-5.7) 1.9 (0.9-3.0) 1.2 (0.2-2.3) 7.5 (0.0-15.8) 0.8 (0.7-0.8)
Favorable Favorable
Moderate Moderate Moderate Moderate Moderate
Unfavorable Unfavorable Unfavorable Unfavorable Unfavorable Unfavorable Unfavorable Unfavorable Unfavorable Unfavorable Unfavorable Unfavorable Unfavorable
Thirty percent of all patients were classified as having a favorable clinical profile with a median survival of 18.6 months (95%CI 15.1-22.1), followed by 29% with a moderate profile and a median survival of 5.9 months (95%CI 4.8-7.0) and 41% with an unfavorable profile and a median survival of 2.2 months (95%CI 1.9-2.6) (figure 2).
Radiotherapy was the most commonly used primary treatment in a total of 997 patients (95%). Only 46 patients (5%) underwent surgery. See table 3 for the radiotherapy regimens and surgical techniques used.
The DBMS database consisted of 342 SBM patients treated with radiotherapy. Median follow-up was 2.2 years and overall median survival was 8.9 months (95%CI 7.4-10.3). In total 258 patients (76%) died during follow-up. Further details of the patient population are published elsewhere4.
56